ANAVIP® [crotalidae immune F(ab’)2 (equine)] is an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.*

Venom Has Met Its Match

LATE COAGULOPATHY
Treating rattlesnake envenomation has both short-term and long-term considerations¹ˑ²
More info
ANAVIP IS DIFFERENT
A PK profile optimized to match rattlesnake venom¹ˑ³ˑ⁴
More info
FULL PRESCRIBING INFORMATION
Download Full Prescribing Information
More info
EFFICACY
Learn how ANAVIP performed in a head-to-head clinical trial¹
More info
SAFETY DATA
Learn about the safety data of ANAVIP in a head-to-head clinical trial⁵
More info
DOSING
Standardized dosing eliminates the need for scheduled maintenance dosing after initial control⁵
More info
VIDEO
From shelf to solution in minutes⁵
Reconstituting and dosing ANAVIP
More info
ANAVIP EXPIRATION DATE EXTENSION
Expiration dates on all current and future lots of ANAVIP have been extended from 24 to 36 months
More info
HOW TO ORDER ANAVIP
Contact your wholesaler or call 1-844-472-7389
More info
EDUCATIONAL RESOURCES
Download educational and reference materials
More info
SUSPECTED ADVERSE REACTIONS
To report suspected adverse reactions, please call the Rare Disease Therapeutics adverse event reporting line at 1-844-472-7389
CONTACT US
Get personal attention to your questions about ANAVIP
More info
INDICATION

ANAVIP® [crotalidae immune F(ab’)2 (equine)] is an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.

Important Safety Information
CONTRAINDICATIONS

None.

ADVERSE REACTIONS

The most common adverse reactions observed in more than 2 percent of patients in the clinical trials for ANAVIP were: pruritus, nausea, rash, arthralgia, peripheral edema, erythema, headache, myalgia, pain in extremity, and vomiting.

WARNINGS AND PRECAUTIONS

Hypersensitivity
ANAVIP may cause allergic reactions.

Patients with known allergies to horse protein are particularly at risk for an anaphylactic reaction. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.

Monitor patients with follow-up visits for signs and symptoms of delayed allergic reactions or serum sickness (rash, fever, myalgia, arthralgia, pruritus, urticarial rash) and treat appropriately if necessary.

Transmissible Infectious Agents
ANAVIP is made from equine (horse) plasma and may therefore carry a risk of transmitting infectious agents, e.g., viruses.

Reactions to Cresol
Trace amounts of cresol from the manufacturing process are contained in ANAVIP. Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient.

 

 

See Full Prescribing Information